Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (NCT05975983)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this revised Phase IIa study is to demonstrate safety of INS018\_055 over 12 weeks in adults with Idiopathic Pulmonary Fibrosis (IPF).
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 40 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- University of Alabama at Birmingham — Birmingham, Alabama
- HonorHealth Research Institute — Scottsdale, Arizona
- Keck School of Medicine of USC — Los Angeles, California
- Florida Lung Asthma and Sleep Specialist — Celebration, Florida
- Central Florida Pulmonary Group, P.A. (CFPG) - Downtown Orlando — Orlando, Florida
- Southeastern Research Center — Winston-Salem, North Carolina
- University of Oklahoma Health Sciences Center (OUHSC) — Oklahoma City, Oklahoma
- Temple University Hospital-Temple Lung Center — Philadelphia, Pennsylvania
- Bogan Sleep Consultants, LLC — Columbia, South Carolina
- University of Texas Southwestern Medical Center — Dallas, Texas
- Metroplex Pulmonary and Sleep Center — McKinney, Texas
- Research Centers of America — McKinney, Texas
📞 Contact the Study Coordinator
Phone: +86 18817554306
Email: Insilico-Clinicaltrial@insilico.ai
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Idiopathic Pulmonary Fibrosis (IPF)
- A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. — Birmingham, Alabama
- Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis — Denver, Colorado
- A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension — Norfolk, Virginia
- Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF) — Palm Spring, California
- The Genetics of Pulmonary Fibrosis — Aurora, Colorado
Explore by condition: All Idiopathic Pulmonary Fibrosis (IPF) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.